Woburn, Massachusetts, USA, August 8, 2026
Replimune Group, Inc. has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting accelerated approval to TUDRIQEV™ (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma whose disease has progressed following anti-PD-1-based immunotherapy. The approval marks the commercialization of Replimune’s first oncolytic immunotherapy and provides a much-needed treatment option for patients with advanced melanoma who have exhausted standard immune checkpoint therapies. TUDRIQEV is a genetically engineered herpes simplex virus type 1 (HSV-1)-based oncolytic viral therapy designed to selectively infect and destroy tumor cells while stimulating a systemic immune response against cancer. Granted under the FDA’s accelerated approval pathway, the decision is based on encouraging clinical evidence demonstrating meaningful and durable responses in patients with limited therapeutic alternatives. The milestone also validates Replimune’s proprietary RPx platform, reinforcing the growing role of viral immunotherapy in modern precision oncology and advancing innovative treatment strategies for aggressive skin cancers.
Clinical Trial Demonstrates Durable Anti-Tumor Responses
The FDA approval is supported by results from the Phase I/II IGNYTE clinical trial, which enrolled 140 patients with advanced melanoma who experienced disease progression despite prior anti-PD-1 therapy. Among the 91 efficacy-evaluable patients, treatment with TUDRIQEV plus nivolumab achieved an objective response rate (ORR) of 24.2%, while responders experienced a median duration of response of 14.1 months, highlighting the therapy’s ability to generate durable clinical benefit in a difficult-to-treat population. The study included patients with advanced Stage IV disease as well as individuals who had previously received adjuvant immunotherapy or exhibited PD-L1-negative tumors. Clinical investigators emphasized that patients with anti-PD-1-resistant melanoma currently face limited treatment options and poor survival outcomes, making the availability of an effective oncolytic immunotherapy particularly significant. The encouraging efficacy data formed the basis for the FDA’s accelerated approval while a confirmatory Phase III IGNYTE-3 trial continues to evaluate long-term clinical benefit.
Novel Viral Immunotherapy Enhances Immune Response
TUDRIQEV utilizes a genetically modified HSV-1 virus engineered to selectively replicate within tumors, causing direct cancer cell destruction while simultaneously stimulating immune recognition of malignant cells. The therapy also expresses GM-CSF and a fusogenic glycoprotein that further enhances immune activation and tumor cell killing. When administered together with nivolumab, TUDRIQEV is designed to overcome immune resistance by promoting a stronger anti-tumor immune response in patients who previously failed checkpoint inhibitor therapy. Treatment is delivered through direct intratumoral injections into superficial, deep, or visceral lesions, with imaging guidance used when necessary for internal tumors. The most commonly reported adverse events included fatigue, fever, chills, nausea, diarrhea, injection-site reactions, musculoskeletal pain, headache, influenza-like illness, rash, cough, and pruritus, while most treatment-related events were mild to moderate in severity, supporting a favorable overall safety profile.
Advertisement
Approval Expands Options for Advanced Melanoma Patients
The accelerated approval establishes Replimune as a commercial-stage biotechnology company while providing oncologists with an innovative treatment option for patients with advanced melanoma who have limited alternatives following checkpoint inhibitor failure. Continued FDA approval will depend upon successful confirmation of clinical benefit in the ongoing Phase III IGNYTE-3 trial, consistent with accelerated approval requirements. The approval also reinforces growing confidence in oncolytic viral therapies as an emerging class of precision cancer immunotherapies capable of complementing existing immune checkpoint inhibitors. As melanoma remains one of the most aggressive forms of skin cancer and many patients eventually develop resistance to PD-1-targeted therapies, the availability of TUDRIQEV represents an important advancement in oncology innovation. By combining viral-mediated tumor destruction with enhanced immune activation, Replimune’s first approved therapy may help improve treatment outcomes while opening new opportunities for future applications of its proprietary RPx oncolytic immunotherapy platform across additional solid tumors.
Source: Replimune press release
